Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to Bydureon (exenatide 2 mg powder and ...

With a view to improve treatment for diabetes patients through innovative technology, product design and development firm Cambridge Consultants in association with AstraZeneca have developed Bydureon ...

(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a ...